Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Modalis Therapeutics stock

4883.T
JP3922600006

Price

99.00
Today +/-
+0.04
Today %
+6.25 %
P

Modalis Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Modalis Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Modalis Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Modalis Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Modalis Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Modalis Therapeutics Stock Price History

DateModalis Therapeutics Price
10/1/202499.00 undefined
9/30/202493.00 undefined
9/27/202493.00 undefined
9/26/202494.00 undefined
9/25/202495.00 undefined
9/24/2024102.00 undefined
9/20/2024101.00 undefined
9/19/2024108.00 undefined
9/18/2024111.00 undefined
9/17/2024122.00 undefined
9/13/202492.00 undefined
9/12/202492.00 undefined
9/11/202492.00 undefined
9/10/202497.00 undefined
9/9/202497.00 undefined
9/6/202496.00 undefined
9/5/2024100.00 undefined
9/4/2024103.00 undefined

Modalis Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Modalis Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Modalis Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Modalis Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Modalis Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Modalis Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Modalis Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Modalis Therapeutics’s growth potential.

Modalis Therapeutics Revenue, EBIT and net profit per share

DateModalis Therapeutics RevenueModalis Therapeutics EBITModalis Therapeutics Net Income
2025e2.07 B undefined0 undefined-157.92 M undefined
20230 undefined-2.37 B undefined-2.39 B undefined
202240.5 M undefined-2.06 B undefined-2.7 B undefined
20211.1 M undefined-1.24 B undefined-738.96 M undefined
2020342 M undefined-398.35 M undefined-448.41 M undefined
2019644.5 M undefined157.19 M undefined140.53 M undefined
201865.3 M undefined-214.12 M undefined-217.91 M undefined

Modalis Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2018201920202021202220232025e
0.070.640.3400.0402.07
-890.77-46.89-99.713,900.00--
-------
0000000
-214157-398-1,239-2,063-2,3700
-329.2324.38-116.37-123,900.00-5,157.50--
-217140-448-738-2,702-2,391-157
--164.52-420.0064.73266.12-11.51-93.43
20.123.5726.3528.7529.1130.970
-------
Details

Keystats

ⓘ

Revenue and Growth

The Modalis Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Modalis Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (B)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
201820192020202120222023
           
1.213.865.424.942.931.88
5.396.60000
000000
000040.316.35
4.2111.1427.07130.8587.7666.53
1.213.875.455.073.061.96
0.7648.9549.77223.7800
000000
000000
00767.8270500
000000
9.0114.510.8873.3168.6169.6
0.010.060.8310.070.07
1.223.946.286.073.132.03
           
0.051.32.712.742.091.22
1.372.624.034.073.422.54
-219.64-79.11-527.52-1,266.48-2,586.42-2,383.84
-0.32-0.08-25.1616.487.32
000000
1.23.846.215.552.941.38
000000
9.9513.7717.1625.6817.7991.79
12.7877.3741.11155.03124.05106.31
000000
000000
22.7391.1458.27180.72141.84198.1
00000412.5
04.7411.895.0500
000334.1646.7634.9
04.7511.89339.2146.76447.4
22.7395.8970.16519.93188.6645.5
1.223.946.286.073.132.03
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Modalis Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Modalis Therapeutics's financial health and stability.

Assets

Modalis Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Modalis Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Modalis Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Modalis Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201820192020202120222023
-213146-439-745-2,707-2,390
0657771230
000000
162-34407994
0839-48767840
000064
130111
-212224-376-747-1,895-2,254
0-54-830-107-197-39
-6-61-830171-185-39
-6-70278110
000000
0000-6481
02.492.80.070.070.74
02.492.780.070.061.22
---20.00---6.00
000000
-0.222.651.56-0.49-2-1.05
-213.16169.86-1,206.59-854.58-2,093.06-2,294.17
000000

Modalis Therapeutics stock margins

The Modalis Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Modalis Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Modalis Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Modalis Therapeutics's sales revenue. A higher gross margin percentage indicates that the Modalis Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Modalis Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Modalis Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Modalis Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Modalis Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Modalis Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Modalis Therapeutics Margin History

Modalis Therapeutics Gross marginModalis Therapeutics Profit marginModalis Therapeutics EBIT marginModalis Therapeutics Profit margin
2025e0 %0 %-7.63 %
20230 %0 %0 %
20220 %-5,094.31 %-6,673.36 %
20210 %-112,676.72 %-67,177.81 %
20200 %-116.48 %-131.11 %
20190 %24.39 %21.8 %
20180 %-327.92 %-333.72 %

Modalis Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Modalis Therapeutics earnings per share therefore indicates how much revenue Modalis Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Modalis Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Modalis Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Modalis Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Modalis Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Modalis Therapeutics Revenue, EBIT and net profit per share

DateModalis Therapeutics Sales per ShareModalis Therapeutics EBIT per shareModalis Therapeutics Earnings per Share
2025e37.62 undefined0 undefined-2.87 undefined
20230 undefined-76.56 undefined-77.24 undefined
20221.39 undefined-70.88 undefined-92.85 undefined
20210.04 undefined-43.11 undefined-25.7 undefined
202012.98 undefined-15.12 undefined-17.02 undefined
201927.34 undefined6.67 undefined5.96 undefined
20183.25 undefined-10.65 undefined-10.84 undefined

Modalis Therapeutics business model

Modalis Therapeutics is one of the most popular companies on Eulerpool.com.

Modalis Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Modalis Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

Modalis Therapeutics shares outstanding

The number of shares was Modalis Therapeutics in 2023 — This indicates how many shares 30.966 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Modalis Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Modalis Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Modalis Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Modalis Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Modalis Therapeutics.

Modalis Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2023-10.17 -16.84  (-65.57 %)2023 Q2
12/31/202212.48 -47.72  (-482.23 %)2022 Q4
9/30/2022-17.38 -18.34  (-5.5 %)2022 Q3
6/30/2022-10.11 -11.57  (-14.47 %)2022 Q2
3/31/2022-12.65 -15.13  (-19.62 %)2022 Q1
12/31/2021-11.96 -19.28  (-61.23 %)2021 Q4
3/31/2021-7.71 7.07  (191.73 %)2021 Q1
1

Modalis Therapeutics shareholders

%
Name
Stocks
Change
Date
5.14371 % KK Life Science Innovation Management2,831,800-2,000,00012/31/2023
4.33839 % Evolution Capital Management, LLC2,388,443-55,5613/6/2024
4.11617 % Nureki (Osamu)2,266,100-290,00012/31/2023
2.58003 % Nikko Asset Management Co., Ltd.1,420,40007/15/2022
2.53389 % Rheos Capital Works Inc.1,395,000-10,0004/25/2023
2.14591 % SBI Investment Co., Ltd.1,181,40004/4/2024
1.85673 % Nomura Securities Co., Ltd.1,022,200-14,5009/27/2023
1.39500 % FIL Investments (Japan) Limited768,000-774,3007/31/2023
1.26612 % SBI Securities Co., Ltd.697,04418,5984/4/2024
0.99903 % Yang-Kaihatsu Co550,000550,00012/31/2023
1
2
3

Modalis Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Astellas Pharma Stock
Astellas Pharma
SupplierCustomer0,74-0,130,19-0,61-0,24-
freee Stock
freee
SupplierCustomer0,65-0,66-0,010,900,95-
Eisai Stock
Eisai
SupplierCustomer0,34-0,40-0,050,920,93-
Editas Medicine Stock
Editas Medicine
SupplierCustomer-0,26-0,67-0,310,840,88-
1

Most common questions regarding Modalis Therapeutics

What is the P/E ratio of Modalis Therapeutics 2024?

The P/E ratio cannot be calculated for Modalis Therapeutics at the moment.

What is the P/S ratio of Modalis Therapeutics 2024?

The P/S cannot be calculated for Modalis Therapeutics currently.

What is the AlleAktien quality score of Modalis Therapeutics?

The AlleAktien quality score for Modalis Therapeutics is 3/10.

What is the revenue of Modalis Therapeutics 2024?

The revenue cannot currently be calculated for Modalis Therapeutics.

How high is the profit of Modalis Therapeutics 2024?

The profit cannot currently be calculated for Modalis Therapeutics.

What is the business model of Modalis Therapeutics

No history available for Modalis Therapeutics.

What is the Modalis Therapeutics dividend?

Modalis Therapeutics pays a dividend of 0 JPY distributed over payouts per year.

How often does Modalis Therapeutics pay dividends?

The dividend cannot currently be calculated for Modalis Therapeutics or the company does not pay out a dividend.

What is the Modalis Therapeutics ISIN?

The ISIN of Modalis Therapeutics is JP3922600006.

What is the Modalis Therapeutics ticker?

The ticker of Modalis Therapeutics is 4883.T.

How much dividend does Modalis Therapeutics pay?

Over the past 12 months, Modalis Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Modalis Therapeutics is expected to pay a dividend of 0 JPY.

What is the dividend yield of Modalis Therapeutics?

The current dividend yield of Modalis Therapeutics is .

When does Modalis Therapeutics pay dividends?

Modalis Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Modalis Therapeutics?

Modalis Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Modalis Therapeutics?

For the upcoming 12 months, dividends amounting to 0 JPY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Modalis Therapeutics located?

Modalis Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Modalis Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Modalis Therapeutics from 10/3/2024 amounting to 0 JPY, you needed to have the stock in your portfolio before the ex-date on 10/3/2024.

When did Modalis Therapeutics pay the last dividend?

The last dividend was paid out on 10/3/2024.

What was the dividend of Modalis Therapeutics in the year 2023?

In the year 2023, Modalis Therapeutics distributed 0 JPY as dividends.

In which currency does Modalis Therapeutics pay out the dividend?

The dividends of Modalis Therapeutics are distributed in JPY.

All fundamentals about Modalis Therapeutics

Our stock analysis for Modalis Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Modalis Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.